Bionix has been recapitalized by Argosy Private Equity
Bionix, LLC has been recapitalized by Argosy Private Equity.
Bionix, headquartered in Toledo, Ohio, was founded in 1984 after identifying a need for disposable ear curettes. Since then, it has become a leading developer of innovative healthcare products for ear, nasal, and wound care applications, among others, that uniquely meet physicians’ needs. Backed by a strong patent portfolio, Bionix is a premium brand for innovative features and superior performance relative to low-cost commodity alternatives. The company manufactures its products in the USA and serves customers in every region of the world.
Argosy Private Equity is a lower middle-market private equity firm which invests in manufacturing and business services companies through management and leveraged buy-outs, recapitalizations, corporate divestitures, growth financings and generational transitions of family-owned businesses.
Oaklins’ team in Cleveland served as the exclusive financial advisor to Bionix.


Talk to the deal team

Andrew P. Male
Managing Director
Cleveland, United StatesOaklins Citizens Capital Markets

Margaret E. Graham
Associate Director
Cleveland, United StatesOaklins Citizens Capital Markets

Savanna Roberts
Associate
Cleveland, United StatesOaklins Citizens Capital Markets
Related deals
Groupe Nature acquires Winco
Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.
Learn moreCamelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.
Learn moreShield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Learn more